Nutriband Inc., a company engaged in the development of prescription transdermal pharmaceutical products, has signed an addendum to the Commercial Development and Clinical Supply Agreement for its lead product, Aversa Fentanyl, that it has in place with its partner, Kindeva Drug Delivery, a global contract development and manufacturing organization (CDMO) focused on drug-device combination products.

The revised agreement formalizes Nutriband and Kindeva’s exclusive product development partnership and long-term commitment. In exchange for milestone payments, the two companies have agreed to share development costs.

Nutriband’s Aversa abuse-deterrent technology is designed to incorporate aversive agents into transdermal patches, preventing the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, such as opioids and stimulants.

Aversa’s unique feature is its proprietary aversive agent coating, which employs taste aversion to deter oral abuse and accidental exposure to transdermal opioid and stimulant patch products.

The technology is protected by a comprehensive international intellectual property portfolio, with patents granted in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

Aversa Fentanyl holds the potential to become the world’s first abuse-deterrent opioid patch, specifically designed to prevent abuse, misuse, and reduce the risk of accidental exposure to transdermal fentanyl patches. With the right market conditions, Aversa Fentanyl has the potential to generate annual sales of $80 million to $200 million in the United States alone.